Evaluation of Molecular Forms of PSA and Human Kallikrein 2 in a Cohort of Patients With Locally Resected Prostate Cancer But Biochemical Recurrence
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 30 - Any |
| Updated: | 3/6/2019 |
| Start Date: | February 2014 |
| End Date: | February 2020 |
The purpose of this study is to investigate if a new blood test looking at PSA and a group of
PSA related proteins in a patient's blood can indicate which men after surgery with a rising
PSA could benefit from treatment, and/or indicate which men are at higher risk for recurrence
before initial treatment is given.
PSA related proteins in a patient's blood can indicate which men after surgery with a rising
PSA could benefit from treatment, and/or indicate which men are at higher risk for recurrence
before initial treatment is given.
Inclusion Criteria:
- All patients treated with radical prostatectomy that develop a rising serum PSA ≥
0.05ng/ml and have not received any kind of additional therapy.
- Patients who have had additional therapy post radical prostatectomy are eligible for
this study if ≥1 year has passed since treatment and the patient develops a rising
serum PSA ≥0.05ng/ml.
Exclusion Criteria:
- Previous additional therapy for prostate cancer, less than 1 year ago
- No evidence of rising PSA
- Patients unwilling to undergo venesection
We found this trial at
1
site
1275 York Ave
New York, New York 10021
New York, New York 10021
(212) 639-2000
Principal Investigator: Vincent Laudone, MD
Phone: 646-422-4306
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
